Casodex Non-Metastatic Prostate Cancer Use Needs More Study – FDA Cmte.
Executive Summary
AstraZeneca's Casodex needs longer-term follow-up data to support an indication for adjuvant therapy following surgery in non-metastatic prostate cancer, FDA's Oncologic Drugs Advisory Committee concluded Dec. 18